Metastatic triple-negative breast cancer: Established and emerging treatments

Akshjot Puri, Tejaswini P. Reddy, Tejal A. Patel, Jenny C. Chang

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Metastatic triple-negative breast cancer (mTNBC) patients tend to have a poor overall survival. The primary goals of treatment focus on palliation of symptoms and improvement in overall survival (OS). Single-agent sequential chemotherapy with anthracycline or taxane has remained the cornerstone of treatment for many years. The FDA has approved newer agents such as poly-adenosine diphosphate-ribose polymerase (PARP) inhibitors upfront in germline BRCA (gBRCA) 1/2 mutation carriers; atezolizumab and nab-paclitaxel combination frontline in patients with PD-L1 expression > 1%; and sacituzumab govitecan (IMMU-132), an antibody-drug conjugate in heavily pretreated mTNBC patients.

Original languageEnglish (US)
Pages (from-to)1793-1796
Number of pages4
JournalBreast Journal
Volume26
Issue number9
DOIs
StateE-pub ahead of print - Jun 23 2020

Keywords

  • PARP inhibitors
  • TNBC
  • advances
  • immunotherapy
  • metastatic

ASJC Scopus subject areas

  • Internal Medicine
  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Metastatic triple-negative breast cancer: Established and emerging treatments'. Together they form a unique fingerprint.

Cite this